Use of compounds aminotriazolopiridinas replaced, in the treatment of inflammatory conditions, autoimmune, proliferative, allergies, Transplant rejection, among others； Pharmaceutical composition that comprises； Pharmaceutical combination.
The present invention relates to the compound according to Formula I, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound inhibits JAK a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the compound, methods for the prophylaxis and/or treatment of diseases involving inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering the compound.USO DE UN COMPUESTO AMINOTRIAZOLOPIRIMIDINA DE FÓRMULA I, UNA SAL, SOLVATO O SAL DE DICHO SOLVATO EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, OSTEOARTRITIS, ENFERMEDADES INFLAMATORIAS DEL INTESTINO, ASMA, CODP, LUPUS ERITEMATOSO SISTÉMICO, DIABETES MELLITUS TIPO I, ARTRITIS PSORIÁSICA, ESPONDILITIS ANQUILOSANTE Y OTRAS.
